Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.

Autor: Fan M; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China., Lu W; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, United States., Che J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States., Kwiatkowski NP; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States., Gao Y; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States., Seo HS; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States., Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States., Gokhale PC; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, United States., Liu Y; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States., Geffken EA; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States., Lakhani J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States., Song K; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States., Kuljanin M; Department of Cell Biology, Harvard Medical School, Boston, United States.; Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana- Farber Cancer Institute, Harvard Medical School, Boston, United States., Ji W; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, United States., Jiang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States., He Z; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States., Tse J; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, United States., Boghossian AS; Broad Institute of MIT and Harvard, Cambridge, United States., Rees MG; Broad Institute of MIT and Harvard, Cambridge, United States., Ronan MM; Broad Institute of MIT and Harvard, Cambridge, United States., Roth JA; Broad Institute of MIT and Harvard, Cambridge, United States., Mancias JD; Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana- Farber Cancer Institute, Harvard Medical School, Boston, United States., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States., Dhe-Paganon S; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States., Zhang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, United States., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States.; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, United States.

Publikováno v: ELife [Elife] 2022 Oct 27; Vol. 11. Date of Electronic Publication: 2022 Oct 27.

Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo.

Autor: Dubiella C; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel., Pinch BJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Chemistry and Chemical Biology, Department of Chemical Biology, Harvard University, Cambridge, MA, USA., Koikawa K; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Zaidman D; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel., Poon E; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Manz TD; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbruecken, Germany., Nabet B; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., He S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Resnick E; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel., Rogel A; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel., Langer EM; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Daniel CJ; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Seo HS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Chen Y; College of Chemistry and Molecular Engineering, Peking University, Beijing, China., Adelmant G; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Sharifzadeh S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Jamin Y; Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK., Martins da Costa B; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Zimmerman MW; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Lian X; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kibe S; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kozono S; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Doctor ZM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Browne CM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Discovery Biology, Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Boston, MA, USA., Yang A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Stoler-Barak L; Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel., Shah RB; Department of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Cell, Developmental and Regenerative Biology, The Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Vangos NE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Geffken EA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Oren R; Department of Veterinary Resources, The Weizmann Institute of Science, Rehovot, Israel., Koide E; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Sidi S; Department of Medicine, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Cell, Developmental and Regenerative Biology, The Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Shulman Z; Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel., Wang C; College of Chemistry and Molecular Engineering, Peking University, Beijing, China., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Dhe-Paganon S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Look T; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.; Division of Pediatric Hematology/Oncology Boston Children's Hospital, Boston, MA, USA., Zhou XZ; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Lu KP; Department of Medicine, Division of Translational Therapeutics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sears RC; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR, USA., Chesler L; Division of Clinical Studies, The Institute of Cancer Research, London, UK., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. nsgray01@stanford.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. nsgray01@stanford.edu.; Department of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA. nsgray01@stanford.edu., London N; Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel. nir.london@weizmann.ac.il.

Publikováno v: Nature chemical biology [Nat Chem Biol] 2021 Sep; Vol. 17 (9), pp. 954-963. Date of Electronic Publication: 2021 May 10.

Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy.

Autor: Jiang L; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Wang YJ; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Zhao J; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Uehara M; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Hou Q; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Institute of Neuroregeneration and Neurorehabilitation, Qingdao University, Qingdao 266071, China., Kasinath V; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Ichimura T; Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Banouni N; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Dai L; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Li X; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Greiner DL; Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA., Shultz LD; The Jackson Laboratory, Bar Harbor, ME 04609, USA., Zhang X; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Sun ZJ; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Curtin I; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Vangos NE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Yeoh ZC; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Geffken EA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Seo HS; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Liu ZX; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Heffron GJ; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115, USA., Shah K; Center for Stem Cell Therapeutics and Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA., Dhe-Paganon S; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, 240 Longwood Ave., Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Abdi R; Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA. Electronic address: rabdi@rics.bwh.harvard.edu.

Publikováno v: Cell [Cell] 2020 Nov 25; Vol. 183 (5), pp. 1219-1233.e18.

Circular RNAs arising from synaptic host genes during human neuronal differentiation are modulated by SFPQ RNA-binding protein.

Autor: Watts, Michelle E.^1,2 (AUTHOR), Oksanen, Marika^1,2,3 (AUTHOR), Lejerkrans, Sanna^1,2 (AUTHOR), Mastropasqua, Francesca^1,2 (AUTHOR), Gorospe, Myriam³ (AUTHOR), Tammimies, Kristiina^1,2,4 (AUTHOR) kristiina.tammimies@ki.se

Publikováno v: BMC Biology. 5/26/2023, Vol. 21 Issue 1, p1-18. 18p.

A novel bivalent interaction mode underlies a non-catalytic mechanism for Pin1-mediated protein kinase C regulation.

Autor: Xiao-Ru Chen, Dixit, Karuna, Yuan Yang, McDermott, Mark I., Imam, Hasan Tanvir, Bankaitis, Vytas A., Igumenova, Tatyana I.

Publikováno v: eLife; 4/30/2024, p1-33, 33p